Opus Genetics, Inc.
IRD
$0.865
$0.00430.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 154.41% | -67.60% | -69.73% | -2.17% | -95.76% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 154.41% | -67.60% | -69.73% | -2.17% | -95.76% |
| Cost of Revenue | 65.56% | 169.36% | 9.38% | -15.28% | 31.01% |
| Gross Profit | -15.60% | -156.16% | -75.66% | 21.24% | -108.29% |
| SG&A Expenses | 123.55% | 40.65% | -22.67% | 104.77% | 58.33% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 101.28% | 114.02% | 4.16% | 19.53% | 26.24% |
| Operating Income | -84.73% | -225.41% | -54.54% | -25.72% | -115.87% |
| Income Before Tax | -632.44% | -235.00% | -56.52% | -22.71% | -114.00% |
| Income Tax Expenses | -- | -- | -- | -- | -100.63% |
| Earnings from Continuing Operations | -632.74% | -235.34% | -56.52% | -22.71% | -114.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -632.74% | -235.34% | -56.52% | -22.71% | -114.13% |
| EBIT | -84.73% | -225.41% | -54.54% | -25.72% | -115.87% |
| EBITDA | -84.79% | -225.37% | -54.54% | -25.72% | -115.86% |
| EPS Basic | -455.06% | -211.03% | -27.04% | -4.77% | -112.78% |
| Normalized Basic EPS | -12.57% | -210.71% | -27.05% | -5.17% | -112.66% |
| EPS Diluted | -455.06% | -216.00% | -27.04% | -4.77% | -113.16% |
| Normalized Diluted EPS | -12.57% | -215.69% | -27.05% | -5.17% | -113.07% |
| Average Basic Shares Outstanding | 32.04% | 21.91% | 23.22% | 17.10% | 10.50% |
| Average Diluted Shares Outstanding | 32.04% | 16.69% | 23.22% | 17.10% | 7.06% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |